Introduction Since the approval of Orthoclone OKT3 in 1986, more than 100 monoclonal antibodies (mAbs) have been approved by the Food and Drug Administration (FDA) to treat a variety of diseases ranging from autoimmune disorders, infectious diseases, and cancer [1-2]. In the context of the current COVID-19 pandemic, it’s crucial that these biologics are developed […]
Change Can Be Challenging: Especially for Patients
Noble Can Help Alleviate Patient Anxieties Caused by Switching to Biosimilar Therapies Change can be difficult for patients, particularly when embarking on a new treatment plan. Patients who require treatments for a variety of chronic illnesses—ranging from diabetes and rheumatoid arthritis to multiple sclerosis, Crohn’s disease and cancer— are increasingly prescribed biosimilar therapies to self-inject […]
Noble’s AdhereIT® Provides Flexibility of Design, Empowers Patients and Encourages Adherence
A recent study1 commissioned by Noble International analyzed the biologic initiation process and current gaps pertaining to patient guidance and self-injection training practices. Anecdotal evidence showed that more than one-third of participating patients lacked the necessary confidence to self-inject during their first six months of treatment due to inadequate training practices. The study further maintained […]
A new way to access scientific papers?
Losing university access doesn’t mean losing access to articles anymore By DeepDyve Digital Library Team Many researchers are surprised to find that leaving university also means leaving behind something they didn’t expect—easy access to peer-reviewed literature. Especially for those who have gone to work at startups or other smaller organizations, finding a way to do […]
Paradigm Shift: How Noble Can Help Patients Reduce Errors During Biologic Initiation
Unmet Training Needs For Patients Using Self-Injectable Drug Therapies Comes At A High Cost A recent report published in Expert Opinion On Drug Delivery uncovered a startling paradigm regarding unmet training needs for patients who begin self-injectable therapies for chronic disease management. The authors of the report, “The current paradigm for biologic initiation: a mixed-methods […]
What needle should you use?
By Nathan Swihart, Social Media and Internet Sales Specialist Every professional should have comprehensive knowledge on the products they use on a daily basis. One of the widest-used and most fundamental tools throughout the history of the medical industry is the hypodermic needle. Whether you work in the laboratory, pharmaceutical, veterinary, or human healthcare fields, […]
Noble can help patients reduce errors when self-administering biosimilar therapies
In today’s evolving healthcare environment, it’s not surprising that biosimilars have become more widely prescribed by physicians as an affordable alternative to biologics, which have been estimated to account for 38-40% of all pharmaceutical spending and average more than $100,000 per patient per year.1 Following this trend, in 2021, the biosimilar global market size was […]
Noble expands its services for its clients into Human Factors
Human Factors + (HF+) is a natural extension of Noble’s deep understanding of the patient experience relative to self-administering drug therapies By Tim McLeroy, Executive Director of Marketing & Patient Services The global market for medical devices is approximately $436 billion, bolstered by an aging population, according to data from hfMEDIC, the University of Utah-led […]
Are you prepared for the upcoming Blanket No Change Certification Reporting Period? Learn more from Reed Tech
Listen to the recording of Reed Tech’s ‘Blanket No Change Certification webinar’ to learn about annual No Change Certification submission requirements for drug product listings and what steps are needed to submit. WATCH NOW FOR: Submission requirements for FDA’s No Change Certification for drug product listings Steps to submit by the December 31 deadline Additional […]
